Eliminating the Public Health Problem of Hepatitis B and C in the United States PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Eliminating the Public Health Problem of Hepatitis B and C in the United States PDF full book. Access full book title Eliminating the Public Health Problem of Hepatitis B and C in the United States by National Academies of Sciences, Engineering, and Medicine. Download full books in PDF and EPUB format.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187
Get Book Here
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187
Get Book Here
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309153689
Category : Medical
Languages : en
Pages : 252
Get Book Here
Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9789241549981
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
Author: Satya Prakash Gupta
Publisher: Academic Press
ISBN: 0128133317
Category : Medical
Languages : en
Pages : 244
Get Book Here
Book Description
Studies on Hepatitis Viruses: Life Cycle, Structure, Functions, and Inhibition presents the latest on this systemic infection that predominantly affects the liver with inflammation that can be acute or chronic. Hepatitis viruses have been the subject of intense study in the last twenty years, with a wealth of information related to their lifecycle, structure, functions and inhibition being presented. This book compiles the most important developments and research, giving users a very useful guide on this evolving area of virology and medicinal chemistry. - Provides comprehensive, state-of-the-art coverage of hepatitis virus infections, the virus' lifecycle, and mechanisms of protease inhibition - Analyzes structure-activity relationships of inhibitors of viral hepatitis - Presents an in-depth view of the structure and function of viral hepatitis - Discusses classification, epidemiology, pathogenesis, natural history, clinical manifestations, diagnosis, complications, associated disorders and animal models
Author: Fred Poordad
Publisher: Elsevier Health Sciences
ISBN: 0323413374
Category : Medical
Languages : en
Pages : 145
Get Book Here
Book Description
Clinical information about Hepatitis C is quickly outdated, so Dr. Poordad has assembled expert authors to provide state-of-the-art clinjcal reviews for hepatologists. This issue is uniquely organized to present articles based on therapeutic regimens for certain types of patients: Regimens for the Treatment-Naïve Patient; Regimens for Treatment of the Interferon-Failure Patient; Regimens for DAA Failure Patients; Regimens for the Cirrhotic Patient; Regimens for the Peri-Transplant Patient; Regimens for the HIV-Co-Infected Patient; and Next-generation Regimens: The Future of HCV Therapy. This presentation will be very clinically relevant for the practicing hepatologist.
Author: Paul Arguin
Publisher:
ISBN:
Category : Travel
Languages : en
Pages : 0
Get Book Here
Book Description
Author: Steven L. Flamm
Publisher: Elsevier Health Sciences
ISBN: 0323548865
Category : Medical
Languages : en
Pages : 193
Get Book Here
Book Description
Consultations of Gastroenterology practitioners are frequently sought for many complex issues relating to acute and chronic liver disease. Many of the disease entities are uncommon and complicated in scope. Liver disease may occur in the setting of other chronic medical conditions and involve other organ systems, with recommendations for diagnostic strategies and therapeutic approaches somewhat challenging. Serious consequences are often the rule with misdiagnosed or inadequately treated liver disease. Dr. Flamm has provided a framework for approaching consultation for common liver-related problems for the gastroenterology practitioner. Articles are devoted to the following topics: Common Findings and Interpretation for the Clinician; Genetic Testing in Liver Disease: What to Order and When; Acute Liver Failure; Liver Disease in Oncology Patients; Primary Sclerosing Cholangitis: What the Gastroenterologist/Hepatologist Needs to Know; An Update on the Treatment and Follow up of Patients with PBC; Wilson’s Disease: Diagnosis, Treatment, and Follow Up; Follow Up of the Post-Liver Transplantation Patient: A Primer for the Practicing Gastroenterologist; Liver Disease in Patients on Total Parenteral Nutrition; Treatment Strategies in NAFLD: What’s Coming; Resistance Testing in Chronic HCV; and HCV genotype 3: Treatment Approach and Natural History.
Author: Philip Rosenthal
Publisher: Elsevier Health Sciences
ISBN: 032389755X
Category : Medical
Languages : en
Pages : 233
Get Book Here
Book Description
In this issue, guest editors bring their considerable expertise to this important topic.Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
Author: Nicholaos Pyrsopoulos
Publisher: Elsevier Health Sciences
ISBN: 032326106X
Category : Medical
Languages : en
Pages : 298
Get Book Here
Book Description
Dr. Pyrsopolous has created a comprehensive review on the most important and timely topics in drug heptatotoxicity. He has arraanged for there to be a full span of very basic articles that discuss drug metabolism, hepatotoxicity, and drug-induced acute liver failure as well as other important articles devoted to clinical manifestations and treatment of drug induced hepatotoxicity; Pathological manifestations of drug induced hepatotoxicity; Drug induced cholestasis; Lipid lowering agents induced hepatotoxicity; Herbal ,complementary and alternative medicine induced liver injury; Antiretroviral and anti - HCV DAA related hepatotoxicity; Antibiotic related hepatotoxicity; Acetaminophen related hepatoxicity; NSAIDS induced hepatoxocity; Chemotherapy induced hepatotoxicity; Anti epileptic induced hepatotoxicity; and steatohepatitis induced by drugs.
Author: David Goldberg
Publisher: Elsevier Health Sciences
ISBN: 032379193X
Category : Medical
Languages : en
Pages : 273
Get Book Here
Book Description
With collaboration from Consulting Editor, Dr. Norman Gitlin Dr. Goldberg has assembled a state-of-the-art issue devoted to management of liver transplant patients. Expert authors have contributed current clinical reviews that covers the breadth of the pre- and post-surgical journey. Articles are specifically devoted to the following topics: Obesity management of liver transplant waitlist candidates and recipients; Expanding the limits of liver transplantation for hepatocellular carcinoma: Is there a limit; Frailty and sarcopenia in patients pre- and post-liver transplant; Achieving tolerance in liver transplantation: Where are we now and what does the future hold; Expanding role of donation after cardiac death donors; Optimizing selection of patients for simultaneous liver-kidney transplant; Keeping the patient with end-stage liver disease alive while awaiting transplant: Management of complications of portal hypertension; Expanding donor selection and recipient indications for living donor liver transplantation; The changing liver transplant recipient: From hepatitis C to NASH and alcohol; Cardiovascular risk stratification in liver transplant candidates; The role of machine perfusion in liver transplantation: Warm, Cold, or does it not matter; Paradigm shift in utilization of livers from hepatitis C-viremic donors into HCV-negative patients; Transplantation of elderly patients: Is there an upper age cutoff; Transplantation for acute alcoholic hepatitis: Controversies and early successes. Hepatologists will come away with the information they need to improve outcomes in liver transplant patients.
